Abstract
Extracorporeal treatments for acute or chronic replacement of organ function still represent a challenge for today’s technology. Activation of fluid phase (complement, coagulation, fibrinolysis) and cellular systems (leukocytes, platelets) is known to occur in hemodialysis (1). Among other biochemical indications of leukocyte activation as a conseguence of blood-surface interactions such as oxygen radicals, release of granulocyte proteinases, monocyte prostaglandin release and cytokine generation, platelet-activating factor (PAF) has drawn interest in various biocompatibility studies (reviewed in 1–5). PAF is a phospholipid mediator of inflammation with different biologic properties relevant for the development of inflammation and septic shock (7–11). PAF may act at concentrations of 10−12M and requires an ether linkage at the sn-1 position of the glycerol backbone, a short acyl chain, usually an acetyl residue, at the sn-2 position, and the polar head group of choline or ethanolamine at the sn-3 position (7–8). However, it has been shown recently that PAF belongs to a family of structurally related phospholipid molecules of biologic origin that shares many physiologic activities (12). PAF is considered a mediator of cell-to-cell communication that may function both as an intracellular and intracellular messenger. PAF is produced after immunologic or nor immunologic challenge by a variety of cells such as monocytes/macrophages, polymorphonuclear neutrophils, basophils and platelets, that may participate in the development of inflammatory reaction (13). In addition, human endothelial cells were found to produce PAF after stimulation by several inflammatory mediators including thrombin, angiotensin II, vasopressin, leukotriene C4 and D4, histamine, bradykinin, elastase, catheprin G, and plastic (14–18). PAF acts in an autocrine and paracrine way through a specific receptor for which a cDNA has been cloned (19,20). The receptor belongs to the family of “serpentine” receptors containing sever a-helical domains that weave in and out plasma membrane and it interacts with a G protein, which activates a phosphatidylinositol-specific phospholipase C (19,20). PAF receptors exist in all cells that are known targets for PAF. Recently, also human cultured endothelial cells have been shown to express PAF receptors (21). PAF promotes the permeability of the EC monolayer leading to cell retraction and formation of intracellular gaps (22). PAF induces in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism (21). The aim of the present review is to briefly summarize early evidence for a role of PAF in bioincompatibility events and to highlight recent advances and their possible potential practical application in testing polymer biocompatibility.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Churchill DN. Efficiency and biocompatibility of membranes. In Dialysis Membranes: Structure and Predictions, V. Bonomini and Y. Berland, Editors, Contributions To Nephrology 113, 1994, 60–71.
Tetta C., David S., Biancone L., Canino F., Cambi V., Camussi G. Role of platelet activating factor in hemodialysis. Kidney Int 1993; 43 (suppl. 39): S154 - S157.
Chenoweth DE. Anaphylatoxin formation in extracorporeal circuits. Complement 1986; 3: 162–165.
Aljama P. Biocompabilidad. Nefrologia 1990; X (3): 18–22.
Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988; 9: 30–35.
Snyder F. Platelet-activating factor and related acetylated lipids as potent biological acting cellular mediators. Am J Physiol 1990; 259: 697.
Pinckard R.N., McManus L., Hanahan D.J. Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelegt-activating factor). Adv lnfflammation Rev 1982; 4: 147.
Venable M.E., Zimmerman G.A., McIntyre T.M., Prescott S.M. Platelet-activating factor: a phospholipid autcoid with diverse actions. J Lipid Res 1993; 34: 691.
Camussi G., Tetta C., Baglioni C. The role of platelet-activating factor in inflammation. Clin Immun Immunopathol 1990; 57: 331.
Yue T.L., Rabinovici R., Feuerstein G. Platelet-activating factor (PAF), a putative mediator in inflammatory tissue injury. Adv Exp Med Biol 1991; 314: 223.
McManus L.M., Woodard D.S., Deavers S.I., Pinckard R.N. PAF Molecular heterogeneity: pathobiological implications. Lab Invest 1993; 69: 639.
Bratton D., Henson P.M. Cellular origin of PAF. In: Platelet-Activating Factor and human Diseases. P.J. Barnes, C.P. Page, P.M. Henson, eds. Blackwell Scientific Publications, London, 1989, p. 23.
Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol 1983; 131: 2397.
Prescott S.M., Zimmerman G.A. McIntyre T.M. Human endothelial cells in culture produce platewlet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA 1984; 81: 3534.
McIntyre T.M., Zimmerman G.A., Satoh K., Prescott S.M. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest 1985; 76: 271.
Camussi G., Tetta C., Bussolino F., Baglioni C. Synthesis and release of platelet-activating factor is ihnibited by plasma a1-proteinase inhibitor or ai-antichymotrypsin and is stimulated by proteinases. J Exp Med 1988; 1681: 293.
Montrucchio G., Bergerone S., Bussolino F. et al. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation 1993; 88: 1476.
Nakamura M., Honda Z.I., Izumi T. et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991; 266: 20400.
Ye R.D., Prossitz E.R., Zuo A., Cochrane C.G. Characterization of a human cDNA that encodes a functional receptor for platelet-activating factor. Biochem Biophys Res Commun 1991; 180: 105.
Camussi G., Montrucchio G., Lupia E. et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995; 154: 6492–6501.
Camussi G., Turello E., Bussolino F., Baglioni C. Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells. Int Arch Allergy Appl Immunol 1991; 96: 84.
Mahiout A., Courtney J.M. Effect of dialyser membranes on extracellular and intracellular granulocyte and monocyte activation in ex vivo pyrogen-free conditions. Biomaterials 1994; 15 (12): 969.
Haeffner-Cavaillon N., Cavaillon JM., Ciancioni C., Bacle F., Delous S., Kazatchine MD. In vitro induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 121–1218.
Tetta C., Segoloni G., Turello E. The production of cytokines in hemodialysis. Blood Purif 1990; 8: 337–346.
Bingel M., Lonnemann G., Koch KM., Dinarello CA., Shaldon S. Plasma interleukin-1 activity during hemodialysis: the influences of dialysis membranes. Nephron 1988; 50: 273–282.
Herbelin A., Nguyen AT., Zingraff J., Urena P., Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor-a. Kidney Int 1990; 37: 116–125.
Laude M., Haeffner-Cavaillon N., Pusineri C. Induction of interleukin-I production during hemodialysis with non-complement activating high-permeability membrane (Abstr). lymphokine Res 1988; 7: 335.
Herbelin A., Urena P., Nguyen AT., Zingraff J., Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954–960.
Luger A., Kovanik J., Stummvoll HK., Urbanska A., luger T. Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987; 32: 84–88.
Blumenstein M., Schmidt B., Ward RA., Ziegler-Heitbrock HWL., Gurland Hi. Altered interleukin-1 production in patients undergoing hemodialysis. Nephron 1988; 50: 277–281.
Chollet-Martin S., Stamatakis G., Bailly S., Mery JP., Gougerot-pacidalo MA. Inducation of tumor necrosis factor-a during hemodialysis: influence of the membrane type. Clin Exp Immunol 1991; 83: 329–332.
Pertosa G., Marfella C., Tarantino EA. et al. Involvement of peripheral blood monocytes in haemodialysis: in-vivo induction of tumor necrosis factor alpha, interleukin-6, and ß,-microglobulin. Nephrol Dial Transplant 1991; 2: 18–23.
Schindler R. Lonnemann G., Shaldon S., Koch KM, Dinarello CA. Transcription, not synthesis of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85–93.
David S. Tetta C., Camussi G. et al. Adherence of human monocytes to haemodialysis membranes. Nephrol Dial Transplant 1993; 8: 1223–1227.
Tetta C., Tropea F., Camussi G. et al. Adherence of human monocytes to haemodialysis membranes: LFA 1 (CD11a/CD18) CRI (CD35) and CR3 (CDL lb/CDI8) triggering promotes the biosynthesis of platelet-activating factor and adherence. Nephrol Dial Transplant 1995; 10.
Lo SK., Detmers PA., Levin SM., Wright SD. Transient adhesion of neutrophils to endothelium. J Exp Med 1989; 169: 1779–1793.
Wright SD., Rao PE., Van Vorrhis WC. et al. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci Usa 1983; 80: 5699.
Wright SD., Meyer BC. Phorbal esters cause sequential activation and deactivation of complement receptors on polymorphonuclear leukocytes. J Immunol 1986; 136: 1759.
Camussi G. potential role of platelet-activating factor in renal pathophysiology. Kidney Int 1986; 29: 469–475.
Elstad MR., Parker CJ., Cowley FS. et al. CD11b/CDI8 integrinb and a b-glucan receptors are in concert to induce the synthesis of platelet-activating factor by monocytes. J Immunol 1994; 152: 220–230.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tetta, C. et al. (1996). The Role of Platelet-Activating Factor in the Biocompatibility of Hemodialysis Membranes. In: Nigam, S., Kunkel, G., Prescott, S.M. (eds) Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology, vol 416. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0179-8_40
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0179-8_40
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0181-1
Online ISBN: 978-1-4899-0179-8
eBook Packages: Springer Book Archive